MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 22 November 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received binding commitments for a capital raising of A$4.8M before costs via a two tranche placement (the “Placement”) of ...
Author: Alex Felman - webdev
-ATH434-201 is a randomized, double-blind, placebo-controlled study in early-stage MSA- -Lead clinical development program enrolled 77 participants globally- MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 08 November 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has successfully ...